Facts and Hopes for Immunotherapy in Renal Cell Carcinoma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2022 Jul 12

PMID 35819272

Authors

Chen Yao

Tian Zhang

Tuoqi Wu

James Brugarolas

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has made a significant impact in many tumors, including renal cell carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of IFNα and IL2, but only a small number of patients had durable clinical benefit. Since then, discoveries of key tumor drivers, as well as an understanding of the contribution of angiogenesis and the tumor microenvironment (TME), has led to advances in drug development, ultimately transforming patient outcomes. Combinations of anti-angiogenic agents with immune checkpoint inhibitors are now standard of care. Current challenges include patient selection for immunotherapy combinations, resistance acquisition, and optimally sequencing therapies. Further discoveries about RCC biology, the TME, and resistance mechanisms will likely pave the way for the next generation of therapies.

Citing Articles

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.

Alhalabi O, Gouda M, Milton D, Momin H, Yilmaz B, Stephen B Cancer Med. 2025; 14(4):e70280.

PMID: 39945382 PMC: 11822648. DOI: 10.1002/cam4.70280.

Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC.

Zhang J, Peng Q, Fan J, Liu F, Chen H, Bi X J Transl Med. 2024; 22(1):1157.

PMID: 39736762 PMC: 11687132. DOI: 10.1186/s12967-024-06018-5.

Renal cell carcinoma and macrophage research: A bibliometric analysis (2004-2023).

Qi D, Zhang H, Xiong F, Zhang G, Tao B, Wang C Medicine (Baltimore). 2024; 103(50):e40954.

PMID: 39686418 PMC: 11651438. DOI: 10.1097/MD.0000000000040954.

Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.

Singh R, Thotakura A, Alati S, Lisok A, Jiang Z, Merino V Front Oncol. 2024; 14:1432286.

PMID: 39324008 PMC: 11423292. DOI: 10.3389/fonc.2024.1432286.

The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.

Seema Mustafa , Jansen C, Jani Y, Evans S, Zhuang T, Brown J Biomark Insights. 2024; 19:11772719241254179.

PMID: 38827239 PMC: 11143877. DOI: 10.1177/11772719241254179.

References

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

Apolo A, Nadal R, Girardi D, Niglio S, Ley L, Cordes L . Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020; 38(31):3672-3684. PMC: 7605393. DOI: 10.1200/JCO.20.01652. View

He R, Hou S, Liu C, Zhang A, Bai Q, Han M . Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016; 537(7620):412-428. DOI: 10.1038/nature19317. View

Hansen U, Ramskov S, Bjerregaard A, Borch A, Andersen R, Draghi A . Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Front Immunol. 2020; 11:373. PMC: 7080703. DOI: 10.3389/fimmu.2020.00373. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Tannir N, Signoretti S, Choueiri T, Mcdermott D, Motzer R, Flaifel A . Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020; 27(1):78-86. PMC: 8589223. DOI: 10.1158/1078-0432.CCR-20-2063. View

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Hwang J, Agarwal N, Brugarolas J, Zhang T . Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. Clin Cancer Res. 2020; 27(1):5-7. PMC: 7785667. DOI: 10.1158/1078-0432.CCR-20-3506. View

Banta K, Xu X, Chitre A, Au-Yeung A, Takahashi C, OGorman W . Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 T cell responses. Immunity. 2022; 55(3):512-526.e9. PMC: 9287124. DOI: 10.1016/j.immuni.2022.02.005. View

10.

Naranbhai V, Viard M, Dean M, Groha S, Braun D, Labaki C . HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021; 23(1):172-184. PMC: 8742225. DOI: 10.1016/S1470-2045(21)00582-9. View

11.

Roussel E, Kinget L, Verbiest A, Boeckx B, Zucman-Rossi J, Couchy G . Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol. 2021; 60(11):1499-1506. DOI: 10.1080/0284186X.2021.1962971. View

12.

Gupta R, Chaim Ornstein M, Li H, Allman K, Wood L, Gilligan T . Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2020; 18(6):429-435. DOI: 10.1016/j.clgc.2019.11.012. View

13.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

14.

Albiges L, Tannir N, Burotto M, McDermott D, Plimack E, Barthelemy P . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020; 5(6):e001079. PMC: 7703447. DOI: 10.1136/esmoopen-2020-001079. View

15.

Borden E . Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019; 18(3):219-234. DOI: 10.1038/s41573-018-0011-2. View

16.

David J, Dominguez C, Hamilton D, Palena C . The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel). 2016; 4(3). PMC: 5041016. DOI: 10.3390/vaccines4030022. View

17.

Dudani S, Graham J, Wells J, Bakouny Z, Pal S, Dizman N . First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019; 76(6):861-867. PMC: 6858928. DOI: 10.1016/j.eururo.2019.07.048. View

18.

Esteban E, Exposito F, Crespo G, Lambea J, Pinto A, Puente J . Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers (Basel). 2021; 13(11). PMC: 8201218. DOI: 10.3390/cancers13112849. View

19.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

20.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View